In continuation to our previous research in understanding the mechanism of NLGP mediated tumor growth restriction, we have reported that therapeutic NLGP treatment significantly reduces the availability of VEGF in tumor hosts, in an immune dependent (CD8+ T cells and IFNγ) manner (21). The gene discussed is VEGFA; the disease is neoplasm.